Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States

Hepatology ◽  
2017 ◽  
Vol 66 (1) ◽  
pp. 46-56 ◽  
Author(s):  
Aijaz Ahmed ◽  
Stevan A. Gonzalez ◽  
George Cholankeril ◽  
Ryan B. Perumpail ◽  
Justin McGinnis ◽  
...  
Keyword(s):  
United States ◽  
Liver Transplant ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Cost Effective ◽  
The United States ◽  
Direct Acting Antivirals ◽  
Cost Effective Treatment ◽  
Direct Acting

Carboplatin-based chemotherapy and surgery: A cost effective treatment strategy for malignant extracranial germ cell tumours in the developing world

2011 ◽  
Vol 57 (1) ◽  
pp. 172-174 ◽  
Author(s):  
Marc Hendricks ◽  
Alan Davidson ◽  
Komala Pillay ◽  
Farieda Desai ◽  
Alastair Millar
Keyword(s):  
Germ Cell ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Developing World ◽  
Cost Effective ◽  
Germ Cell Tumours ◽  
Cost Effective Treatment

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

2019 ◽  
Vol 68 (2) ◽  
pp. 379-387 ◽  
Author(s):  
Calvin Q. Pan ◽  
Vijay Gayam ◽  
Charles Rabinovich ◽  
Milana Normatov ◽  
Bazhena Fidman ◽  
...  
Keyword(s):  
United States ◽  
Older Adults ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
The United States ◽  
Large Cohort ◽  
Direct Acting Antivirals ◽  
Direct Acting

scholarly journals Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Stephen E. Congly ◽  
Rhea A. Varughese ◽  
Crystal E. Brown ◽  
Fiona M. Clement ◽  
Lynora Saxinger
Keyword(s):  
United States ◽  
Health Care ◽  
Cost Effectiveness ◽  
Supportive Care ◽  
Health Care System ◽  
Cost Effective ◽  
The United States ◽  
Cost Effective Treatment ◽  
Severe Infections ◽  
Care System

AbstractDespite COVID-19’s significant morbidity and mortality, considering cost-effectiveness of pharmacologic treatment strategies for hospitalized patients remains critical to support healthcare resource decisions within budgetary constraints. As such, we calculated the cost-effectiveness of using remdesivir and dexamethasone for moderate to severe COVID-19 respiratory infections using the United States health care system as a representative model. A decision analytic model modelled a base case scenario of a 60-year-old patient admitted to hospital with COVID-19. Patients requiring oxygen were considered moderate severity, and patients with severe COVID-19 required intubation with intensive care. Strategies modelled included giving remdesivir to all patients, remdesivir in only moderate and only severe infections, dexamethasone to all patients, dexamethasone in severe infections, remdesivir in moderate/dexamethasone in severe infections, and best supportive care. Data for the model came from the published literature. The time horizon was 1 year; no discounting was performed due to the short duration. The perspective was of the payer in the United States health care system. Supportive care for moderate/severe COVID-19 cost $11,112.98 with 0.7155 quality adjusted life-year (QALY) obtained. Using dexamethasone for all patients was the most-cost effective with an incremental cost-effectiveness ratio of $980.84/QALY; all remdesivir strategies were more costly and less effective. Probabilistic sensitivity analyses showed dexamethasone for all patients was most cost-effective in 98.3% of scenarios. Dexamethasone for moderate-severe COVID-19 infections was the most cost-effective strategy and would have minimal budget impact. Based on current data, remdesivir is unlikely to be a cost-effective treatment for COVID-19.

Sign in / Sign up

Export Citation Format

Share Document